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Lengthy, antimicrobial therapy targeting the pathogen is the mainstay of conventional 
tuberculosis treatment, complicated by emerging drug resistances. Host-directed ther-
apies, including non-steroidal anti-inflammatory drugs (NSAIDs), in contrast, target host 
factors to mitigate disease severity. In the present Systematic Review, we investigate 
whether NSAIDs display any effects as therapy of TB and discuss possible mechanisms 
of action of NSAIDs as adjunctive therapy of TB. Ten studies, seven preclinical studies in 
mice and three clinical trials, were included and systematically reviewed. Our results point 
toward a beneficial effect of NSAIDs as adjunct to current TB therapy regimens, mediated 
by decreased lung pathology balancing host-immune reaction. The determination of the 
best timing for their administration in order to obtain the potential beneficial effects needs 
further investigation. Even if the preclinical evidence requires clinical evaluation, NSAIDs 
might represent a potential safe, simple, and cheap improvement in therapy of TB.
Keywords: non-steroidal anti-inflammatory drugs, host-directed therapies, tuberculosis, systematic review, 
infectious diseases
iNTRODUCTiON
Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis (Mtb) caus-
ing a wide spectrum of disease in humans (1). The current approach to treat TB entails antimicrobial 
drugs that target mycobacteria (2). Drugs to target host immune function rather than focusing on the 
bacteria have been proposed as adjuvants to classic antimicrobial treatment, with the advantage of not 
selecting TB drug resistance (3). The wide range of these host-directed therapies (HDTs)—includ-
ing NSAIDs (4)—act on host immune effectors to achieve decrease in host-destructive pathology; 
potentially leading to clinical improvement, decreased morbidity, and mortality. Pathologic immune 
reactions in the host, such as insufficient or excessive inflammatory response leading to severe tissue 
damage are considered a major cause of failure of current TB treatment (5).
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Neutrophils represent a protective immune response in 
early infection through secretion of oxidizing and hydrolytic 
agents targeted at the bacteria (6). While this neutrophil-
dominated inflammation is beneficial in the acute infection, 
it can be detrimental in the context of chronic infection (6). 
Excessively aggressive immune response in active, chronic TB 
disease destroys host tissue leading to necrosis and cavitation, 
facilitating spread of the bacilli (7). Attenuating excessive host 
inflammatory response in active TB might thus be beneficial 
during treatment and for disease outcome (6). NSAIDs, based 
on their anti-inflammatory effect, could act on attenuating 
excessive (neutrophil-mediated) inflammation in active TB 
disease (4, 6, 8).
The aim of this review was to investigate whether NSAIDs are 
a useful HDT candidate for TB. With this purpose, we systemati-
cally reviewed the published manuscripts on the preclinical and 
clinical effects of NSAIDs when used as therapy of TB, alone 
or in combination with commonly used anti-TB drugs or BCG 
vaccination.
MeTHODS
We used the 2009 PRISMA guidelines to systematically review 
PubMed for studies published until January 2017 that evaluate 
NSAIDs as therapy of TB. The following search terms were used: 
“tuberculosis” OR “mycobacterium tuberculosis” combined with 
drug names of the NSAID group: ((tuberculosis OR (mycobac-
terium tuberculosis)) AND (ibuprofen OR aspirin OR naproxen 
OR etoricoxib OR indomethacin OR meloxicam OR celecoxib 
OR diclofenac (DCL) OR oxyphenbutazone OR carprofen) NOT 
“review” [publication type]).
Two investigators independently reviewed the title and abstract 
of all identified publications for relevance. Studies were deemed 
relevant when they met the following criteria: clinical or animal 
studies, English language, published on Pubmed from 1950 
through January 2017, study subjects are TB patients (sensitive 
and resistant, pulmonary and extra-pulmonary), who received a 
drug from the NSAID-group. We excluded in vitro, open-label, 
and self-reporting studies as well as Case Reports. The reference 
list of included publications was furthermore screened for relevant 
publications. Disagreements between investigators were resolved 
by discussion. The full text of the included studies was reviewed 
for relevant information to answer the question whether NSAIDs 
as HDTs are beneficial during TB treatment. Information was 
systematically collected according to predetermined criteria, i.e., 
drug, study, experimental approach, TB patients/mouse strain, 
sample size, intervention, and outcome.
Two investigators independently reviewed the full text of all 
identified publications. For clinical trials (CTs), the Jadad Scoring 
System was used to evaluate quality (9).
ReSULTS
A total of ten relevant studies were identified and included for 
systematic review (Table 1). The full texts of all ten studies were 
retrieved for in depth analysis. The three CTs (10–12) were of 
high quality, according to Jadad scoring.
ibuprofen and Aspirin
Ibuprofen acts as an unselective cyclooxygenase (COX)-inhibitor. 
COX control the production of lipid mediators derived from 
arachidonic acid, such as prostaglandins (PGs), resolvins, lipox-
ins, leukotriene, and thromboxanes (TXAs). Three studies were 
found for Ibuprofen (13–15).
Acetylsalicylic acid (AAS) is a non-selective COX-inhibitor, 
which irreversibly inhibits COX-enzymes. In addition to its 
anti-inflammatory effects, it is widely used in prevention of car-
diovascular disease and strokes (20) due to its cardio-protective 
effects mediated by irreversible inhibition of TXA A2 production 
in nuclei-free platelets. Five studies were identified for Systematic 
Review of aspirin (10–12, 14, 15).
Vilaplana et  al. treated Mtb infected C3HeB/FeJ mice—in a 
murine model of active TB—with 80 mg/kg/day ibuprofen (13). 
Ibuprofen increased survival and significantly decreased the 
number and size of lung lesions consistent with decreased bacil-
lary loads in the lungs. Histologic examination revealed excessive 
neutrophilic infiltration in the control group, which was found to 
be alleviated in the Ibuprofen-group (13).
Byrne et al. treated Mtb-infected mice with either the first-
line anti-TB drugs pyrazinamid (Z) or isoniazid (H), or with the 
NSAIDs ibuprofen or aspirin, alone or in combination with H. 
Treatment was started 1 day after infection (14). Compared to 
controls, Z alone reduced bacterial counts significantly in lungs 
and spleens. Ibuprofen with H enhanced this effect, while with 
aspirin reduced it. Ibuprofen and aspirin alone did not have 
any significant effect on bacterial counts compared to controls 
but enhanced the clearance of Mtb in tissues achieved by H. 
The authors suggest the use of ibuprofen rather than aspirin as 
adjunctive analgesic in TB-treatment (14). However, another 
in  vivo study by Byrne et  al. showed that both ibuprofen and 
aspirin enhance the effect of Z and might be evaluated to shorten 
therapy (15). Mtb-infected mice were treated with aspirin (20 mg/
day), ibuprofen (20  mg/day) or Z (150  mg/day) alone or Z in 
combination with either aspirin or ibuprofen, from one day after 
infection. Z alone reduced bacterial counts compared to controls, 
and this effect was enhanced by both aspirin and ibuprofen (15).
Two CT were found supportive of the synergistic effect of 
aspirin and Z: short-term, low-dose aspirin was shown to prevent 
the side effect of hyperuricaemia in Z-treatment of TB (12). Petty 
et al. treated TB patients who received anti-TB treatment with Z 
(and H and ethionamide) with additional oral low-dose aspirin 
2.4 g/day for three consecutive days. Short-term, low-dose aspirin 
significantly lowered serum uric acid concentrations to almost 
normal levels in all enrolled patients, and in three patients who 
presented with mild arthralgias, AAS controlled them. In line 
with the results from Petty et al., aspirin has been vsuggested to 
ameliorate arthralgia in Z-treatment of TB (11). Horsfall et  al. 
followed patients with arthralgia during common TB-therapy 
containing Z, administered with additional anti-arthralgia 
treatment: aspirin 2.4  mg/day or allopurinol 200  mg/day or a 
placebo (11). Most patients in all three treatment groups reported 
improvement, though the improvement was greater and faster in 
in the aspirin group (11).
Schoeman et  al. conducted a double-blind, randomized 
phase II CT to evaluate the effect of aspirin-treatment as an 
TAbLe 1 | An overview on the data acquisition from relevant studies for systematic review.
Drug Reference experimental 
approach
Patients/
mouse strain
Sample size intervention Outcome
Aspirin and 
Ibuprofen
Vilaplana 
et al. (13)
Murine model of 
active TB: mice 
infected with Mtb 
were treated with 
ibuprofen when their 
health started to 
deteriorate 
C3HeB/FeJ 
mice
60 Infection of mice i.v. with Mtb 
H37Rv. Oral ibuprofen treatment 
80mg/kg/day *week 3 or week 
4 after infection
Reduction in the no. and size of lung 
lesions, significantly decreased bacillary 
load in lungs and increased survival in 
ibuprofen group
Byrne et al. 
(14)
Murine model: 
mice infected with 
Mtb were treated 
with Isoniazid (H) in 
combination with 
aspirin or ibuprofen
BALB/c mice 30 Aerosol infection of mice 
with Mtb H37Rv. *1 day after 
infection, 5 days/week/4 weeks 
oral aspirin or ibuprofen 
(respectively, 10, 20, and 
40 mg/kg) alone, or isoniazid 
(25 mg/kg) in combination with 
aspirin or ibuprofen, respectively
Aspirin or ibuprofen alone: no significant 
effect on CFU counts. Isoniazide (H) alone: 
reduction of CFU counts. Ibuprofen with 
(I): further decrease of CFU counts. Aspirin 
with (I): increased CFU counts (compared 
to H only)
Byrne et al. 
(15)
Murine model: mice 
infected with Mtb 
were treated with 
aspirin, ibuprofen or 
pyrazinamid (Z) alone 
or in combination 
in initial phase of 
disease
BALB/c mice 30 Aerosol infection of mice 
with Mtb H37Rv. *1 day after 
infection, 5 days/week/4 weeks 
oral aspirin (20 mg/day) or 
ibuprofen (20 mg/day) or 
pyrazinamid (150 mg/day), 
alone, or pyrazinamid in 
combination with aspirin or 
ibuprofen
Aspirin or ibuprofen alone: no significant 
effect on CFU counts. Pyrazinamide 
alone: reduction of CFU counts. Aspirin or 
ibuprofen with Z: further reduction of CFU 
counts
Petty et al. 
(12)
Clinical trial (CT): 
assessment of 
serum uric acid 
concentrations in TB 
patients treated with 
Z (and ethionamide 
and H) before, during 
and after additional 
treatment with low-
dose aspirin; three 
patients presented 
with arthralgias
TB patients; 
no laboratory 
signs of renal 
impairment, 
not treated 
with urate 
retaining drugs, 
no special diet
11 Enrolled patients had received 
Z for 3 days to 18 months; 
oral acetylsalicylic acid (AAS) 
2.4 g/day was added for three 
consecutive days. Serum uric 
acid was measured: on 2 days 
during Z-only treatment before 
AAS was added; on day 2 and 
3 of additional AAS-treatment; 
2 days after end of additional 
AAS-treatment
Low-dose aspirin (2.4 g/day 3 days) 
significantly lowered serum uric acid to 
almost normal levels (mean pre-AAS: 
8.67 mg/100 ml; AAS 4.56 mg/100 ml; 
post-AAS 8.43 mg/100 ml) in all 11 
patients; when taken out after 3 days, 
levels immediately returned to pre-AAS 
treatment levels; in one patient additional 
AAS treatment was continued for 8 weeks; 
after which serum uric acid concentration 
remained low; in three patients AAS 
attenuated mild arthralgias
Horsfall 
et al. (11)
CT: patients with 
arthralgia during 
treatment with (Z) 
were treated with 
allopurinol or aspirin
Patients with 
arthralgia 
during 
treatment with 
(Z)
60 Anti-arthralgia treatment for 
8 weeks: n = 18 aspirin 2.4 mg/
day, n = 23 allopurinol 200 mg/
day, n = 19 placebo only 
(randomly allocated)
Most patients improving joint symptoms 
and signs. More in aspirin and placebo 
groups, most rapid in aspirin group; only 
in aspirin group, mean serum uric acid 
concentration lower during treatment than 
before
Schoeman 
et al. (10)
CT: children with 
probable diagnosis 
of TBM (*at least 
clinical signs and CFU 
changes typical for 
TBM) were treated 
with low-or high-dose 
aspirin or a placebo 
added to anti-TB 
treatment
Children with 
diagnosis of 
probable* TBM
159 enrolled, 
146 included, 
rest excluded 
because 
pre-treated 
with aspirin, 
but included in 
open-label trial
n = 50: placebo group (daily 
sorbitol); n = 47: low-dose 
aspirin group (daily 75 mg); 
n = 49: high-dose aspirin group 
(daily 100 mg). Monitoring for 
side effects
8 deaths: 1 placebo group, 2 low-dose 
aspirin group, 3 high-dose aspirin group, 
2 open-label group (1 death in may have 
been due to aspirin). Motor outcome: no 
significant differences, but of 9 children who 
developed hemiplegia, none in the high 
dose aspirin group. Cognitive outcome: 
Griffiths test (after 6 months of treatment) 
no significant differences
Indomethacin Shroff et al. 
(16)
Murine model: mice 
i.p. immunized with 
M. vaccae and 
pre-treated with 
indomethacin were 
infected with Mtb
BALB/c and 
Swiss white 
mice
50 6 i.p. (50 μg/mouse) i.p. 
injections at 12 h intervals of 
indomethacin, 12 h after last 
dose i.p. immunization with 
M. vaccae. Control 1: no pre-
treatment, but immunization. 
Control 2: no immunization
Immunized, indomethacin pre-treated mice 
did show immunization response (CPE 
0.18). Immunized, non-pre-treated mice 
didn’t show immunization response (CPE 
0.02)
(Continued)
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TAbLe 2 | Treatment groups in Schoeman et al. (10).
Group Dosage (no. of 
patients)
Anti-tb 
treatment
Monitoring for 
side-effects
Placebo Daily sorbitol 
(n = 50)
Daily H, R, E 
(20 mg/kg/day)
Daily: GIT- and 
bleeding disorders
Low-dose 
acetylsalicylic 
acid (AAS)
75 mg/day (n = 47) Daily Z (40 mg/
kg/day)
Weekly: liver function, 
Reye-syndrome
High-dose AAS 100 mg/day 
(n = 49)
Daily prednisone 
(4 mg/kg)
Drug Reference experimental 
approach
Patients/
mouse strain
Sample size intervention Outcome
Hernandez 
et al. (17)
Murine model: mice 
with induced lung 
granulomas of TB 
were treated with 
indomethacin or 
Cyclophosphamid 
(INN)
BALB/c mice ? Culture filtrate proteins 
(CFP) obtained from Mtb. 
Immunization of mice with 
CFP or mBSG. After 10 days 
intra-tracheal infection with 
CFP- or mBSG-coated beads 
(control). For testing effect of 
indomethacin and INN: 5 mg/
kg/day i.p. administration of 
indomethacin during the whole 
experimental procedure, 20 mg/
kg i.p. injection of INN 1 day 
before infection
CFP-granulomas significantly bigger 
than mBSA-granulomas, CD8+ T-cells 
dominating, reduced DTH and antibody 
titers. Upon treatment with INN or 
Indomethacin; significant reduction of 
granuloma size, increase in DTH and 
antibody titers. mBSA-granulomas, 
composed quite equally of CD8+ and 
CD4+ T-cells, did not alter antibody titers
Diclofenac 
(DCL)
Dutta 
et al. (18); 
in vivo part 
discussed 
here, 
in vitro part 
not further 
mentioned 
here
Murine model: mice 
were injected with 
10 mg/kg DCL and 
then challenged with 
a 50 median lethal 
dose of potent clinical 
isolate Mtb H37Rv102
Swiss white 
mice
Groups of 20, 
how many 
groups?
Parenterally infection with 
0.05 ml suspension (0.5 mg 
homogenized culture KLM, 
Kirchers Liquid medium) 
equaling c < 9 × 109 CFU). 
Of each group, 10 mice were 
DCL-treated (10 mg/kg/day) 
for 6 weeks, 10 not treated as 
control
DCL-treated mice: less tubercles and 
none in the lungs (compared to control). 
Histophathological section of liver: 
significantly less infiltrations in DCL-treated 
mice. Smears for acid-fast bacilli (by Z-N 
strain) positive for all 10 untreated mice, 
only in 4 DCL-treated mice. Mtb recovery in 
subculture from 5 control mice and 1 DCL-
treated mice (P < 0.01)
Dutta 
et al. (19); 
in vivo part 
discussed 
here, 
in vitro part 
not further 
mentioned 
here
Murine model: 
mice infected with 
Mtb were treated 
for with either DCL 
or Streptomycin 
(S) alone, or in 
combination.
Swiss albino 
mice
210 I.v. infection of mice with Mtb 
H37Rv; 5 treatment groups: 
(1) day 1 control (baseline 
values for spleen weight), (2) 
untreated control, (3) DCL-
treated (10 μg/g/day, orally), 
(4) STM-treated (150 μg/g/
day, subcutaneously), (5) DCL+ 
STM-treated (STM 1 h after 
DCL); for 4 weeks
Treatment with either DCL or STM alone 
significantly reduced bacterial counts in 
lungs and spleen and mean spleen weight, 
and increased survival (compared to 
control). Simultaneous administration further 
decreased bacterial counts and spleen 
weight and increased survival significantly 
(also compared to STM only)
Total number 10
TAbLe 1 | Continued
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add-on to standard anti-TB treatment (and prednisone) on 
mortality and morbidity of children with a probable diagnosis 
of tuberculous meningitis (TBM) (10). The primary endpoints 
were survival, motor and cognitive outcome and the number 
of serious adverse events. Patients were randomly grouped into 
three adjunctive treatment groups (Table 2). There was no effect 
of aspirin on the outcome of hemiplegia when it was already 
present at admission, though of nine children who developed 
hemiplegia, none was in the high dose aspirin group. In total, 
eight children died, relatively equally distributed to all three 
treatment groups, one death possibly caused by aspirin treat-
ment (75  mg/day) (10). Results did not show any significant 
beneficial or adverse effect of aspirin. The high-dose aspirin 
group in this study turned out to have worse baseline character-
istics at start, with more hemiparesis at baseline, which might 
have distorted the results (10).
indomethacin
Indomethacin is a non-selective COX-inhibitor and a non-
salicylate NSAID similar to ibuprofen. Two studies were identi-
fied which furthermore provide special insights into apparent 
immune-modulatory properties of NSAIDs-like indomethacin 
(16, 17).
A study by Hernandez-Pando et al. evaluated immunosuppres-
sive phenomena based on T-cell imbalance in the TB-granuloma 
and its treatability with cyclophosphamide and indomethacin 
(17). Cyclophosphamide is an alkylating agent used during 
cancer-treatment and for autoimmune-disorders. Mice were 
immunized against Mtb and 10 days after immunization, infected 
with Mtb-coated beads to induce granuloma formation. To evalu-
ate their effect, 5  mg/kg/day indomethacin was administered 
intraperitoneally (i.p.) during the whole experimental procedure 
and 20 mg/kg cyclophosphamide was injected i.p. 1 day before 
infection. Control granulomas induced by mBSA-coated beads 
were composed quite equally of CD8+ and CD4+ T-cells and 
FiGURe 1 | COX and 5-LOX pathways of eicosanoid biosynthesis from arachidonic acid. The physiological role of each eicosanoid and eicosanoid group is 
explained. The figure shows where the non-steroidal anti-inflammatory drugs (NSAIDs) evaluated in this review have an effect, blocking both COX enzymes or the 
COX-2 selectively. By inhibiting the COX enzymes, NSAIDs inhibit prostaglandin synthesis. They also promote a switch to arachidonic acid oxidation by 5-LOX. COX, 
cyclooxygenase; LOX, lipoxygenase; TXA, thromboxane; TXAS, thromboxane synthase; PG, prostaglandin; PGDS, PGD synthase; PGFS, PGF synthase; PGES, 
PGE synthase; PGIS, PGI synthase; LT, leukotriene; LTC4S, LTC4 synthase; LTA4H, LTA4 hydrolase; LX, Lipoxin.
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did not alter antibody titers against Mtb. TB granulomas were 
significantly bigger, mainly composed of CD8+ cytotoxic T-cells 
and showed a drop in DTH-reaction (delayed type hypersensitiv-
ity reaction) and antibody titers against Mtb. This imbalance was 
reversible upon administration of indomethacin or cyclophos-
phamide with significant reduction of granuloma size, increase 
in DTH and antibody titers. Conclusively, an imbalance in T-cells 
within TB-induced granulomas mainly being composed of CD8+ 
cytotoxic T-cells, and few CD4+ T-helper cells down-regulates 
cell-mediated and humoral immunity to Mtb locally. This is 
reversible upon treatment with indomethacin (17).
Shroff et al. found that indomethacin enhance the response of 
mice to intraperitoneal immunization with M. vaccae (16). Mice 
were pre-treated with indomethacin and then immunized with M. 
vaccae. After 48 h DTH-reaction was tested, the non-pre-treated 
did not show any reaction of immunization, the pre-treated mice 
did show immunization responses. Thus, the non-responder state 
of mice to M. vaccae by i.p. route of immunization was corrected 
by pre-treatment with indomethacin (16).
Diclofenac
Diclofenac is an unselective COX-inhibitor with anti-bacterial 
properties. Anti-mycobacterial action has been shown in two 
animal studies (18, 19).
Dutta et  al. treated Mtb-infected mice with DCL shortly 
after infection (18), the DCL-treated mice showing less lesions 
and lower bacillary loads (measured by positive smears for 
acid-fast bacilli and positive subculture for Mtb) compared to 
controls (18).
A second study by Dutta et  al. showed synergistic activity 
of DCL in combination with Streptomycin (S) (19). Mice were 
infected with Mtb and treated with DCL, S or S + DCL in com-
bination (19). Both, treatment with S or DCL alone decreased 
bacterial counts in lungs and spleens and mean spleen weight, 
and increased survival. All these effects were increased by the 
simultaneous administration of S + DCL (19).
DiSCUSSiON
Our results are based on the search for specific NSAID drug names, 
we include only English written articles and exclude open-label 
and self-reporting studies as well as Case Reports. These restric-
tions in the search strategy impose a selection bias on results. Our 
review combines results, expressed as various endpoints, from ten 
different studies, where experimental approach, patients, sample 
size, and intervention differ (see Table 1). Figure 1 shows two of 
the main pathways (COX and 5-LOX) of eicosanoid biosynthesis 
from arachidonic acid, and where the NSAIDs have an effect.
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Though in total 10 studies were identified for Systematic 
Review, the anti-inflammatory effect of NSAIDs was only inves-
tigated as an endpoint (granuloma size in lungs) by two studies, 
which furthermore assessed differing characteristics of assessed 
granulomas (13, 17). However, all seven reported animal studies 
provide evidence for a clear beneficial effect of NSAIDs in TB 
(expressed by various endpoints), and two of three reported CT 
found mild beneficial effects of aspirin alleviating side-effects of 
Z (11, 12). Included animal studies did not report side-effects of 
treatment with NSAIDs. The three CTs reported no severe side 
effects except two, including one death, which underline the 
importance of monitoring for risk factors and side-effects when 
investigating NSAIDs in general (10). To conclude, our results 
from seven animal studies point to a clear beneficial effect of 
NSAIDs in TB, but the individually reported beneficial effects 
need more investigation and, when supported, consequently 
clinical confirmation.
Regarding the animal studies included, need to remember 
that humans respond with a wide spectrum to infection with 
Mtb, from innately resistant to extremely susceptible (21). Key 
factor for survival of Mtb in the human host is the induction of 
lung necrosis, which enables spreading of the bacilli (21). The 
immunologic response to Mtb infection in mice is largely geneti-
cally determined (21). None of the currently available models in 
mice represents the whole spectrum of human TB, but specific 
models match specific phenotypes and pathways of inflammation 
of human TB (21). The two most commonly employed inbred 
laboratory mouse strains [C75BL/6 (B6) and BALB/c mice] do 
not develop necrotic lesions (21), in spite of developing chronic 
asymptomatic infection. There are animal models available 
which effectively mimic lung necrosis of the susceptible human 
individual, i.e., the C3HeB/FeJ model mimics both necrosis and 
cavitation (21). Therefore, the choice of the specific animal model 
matching the specific research question is of great importance. 
Vilaplana et al. employ C3HeB/FeJ mice to evaluate the effect of 
ibuprofen on lung pathology in TB (13). Four of the seven ani-
mal studies assessed employed BALB/c mice (Table 1) to assess 
ibuprofen and aspirin as adjunct to commonly used TB drugs 
(14, 15), to evaluate the effect of indomethacin on vaccination 
with M. vaccae (16) and to study the effect of indomethacin on 
granuloma composition (specifically T-cell balance) (17). Dutta 
et al. employ Swiss white mice to assess the anti-bacterial effect 
of DCL (18, 19).
According to the results of our Systematic Review, NSAIDs 
can be beneficial if given as co-therapy during TB therapy. This 
protective effect is possibly mediated by their anti-inflammatory 
properties, by enhancing activity of TB-antibiotics and possibly 
by own directly bactericidal activity.
Excess recruitment of granulocytes (primarily neutrophils) 
leads to uncontrolled inflammation and exacerbation of TB 
disease (6, 22). Infection of macrophages leads to a neutrophilic-
dominated inflammatory response (8, 13), which—in absence of 
sufficient Mtb-elimination—leads to an excessive, neutrophilic-
dominated, inflammatory response, and disease exacerbation: 
eventually, the host succumbs to infection, before the adaptive 
immune response can fully start working (7, 22, 23). NSAIDs 
could impact on these interactions by reducing the destructive 
inflammatory response via inhibition of PGE2 in granulo-
cytes as well as by enhancing effectors of adaptive immunity 
such as IFN-γ (4, 24, 25). In agreement with this hypothesis, 
Vilaplana et  al. found that neutrophils are of major responsi-
bility for chronic inflammation and tissue damage associated 
with granulomas (8), and that the anti-inflammatory properties 
of NSAIDs can mitigate this phenotype (8, 13). Findings by 
Hernandez-Pando and Shroff et  al. point to NSAIDs possibly 
balancing cell-mediated, adaptive immune response to Mtb. 
Hernandez-Pando et al. found that indomethacin can balance 
CD8+- and CD4+-ratio in TB-granulomas reducing excessive 
inflammation and morbidity (17).
The reduction of prostaglandin E2 (PGE2) is considered one 
mechanistic explanation underlying the anti-inflammatory bene-
fit of NSAIDs in the context of Mtb infection (4), as PGE2 inhibits 
phagocytosis and bacterial killing at late stage of Mtb-infection. 
However, a protective effect of PGE2 on the mitochondrial 
membrane against Mtb in macrophages has been described, sug-
gesting it to be beneficial at early stages (4). Another explanation 
is NSAIDs action against PG-production in polymorphonuclear 
leukocytes in late stage Mtb-infection, as all these cells are highly 
implicated in the formation and maintenance of granulomas (4, 7). 
They all possess COX-2 activity producing PGs and therefore 
drive the chronic inflammation and tissue damage associated with 
granulomas in late Mtb-infection (4). For all these, an accurate 
evaluation of the timing of NSAIDs as an add-on in TB-treatment 
is warranted. The beneficial effect of NSAIDs is based on their 
ability to reduce excessive and tissue-damaging inflammation 
mainly in late stage infection. They may control liquefaction of 
the granulomas and consequently enhance healing (4, 13); thus 
might have positive effects in patients with active TB, usually 
present after months of infection.
On the other hand, patients with severe TB-disease are at 
higher risk of developing thrombosis and stroke, due to an hyper-
coagulable state in advanced stages of the diseases (26). Low-dose 
aspirin is proven to have protective effects in other patients at 
risk of developing ischemic stroke (20). Though in the reviewed 
CT by Schoeman et  al. anti-coagulative therapy with low-dose 
aspirin did not show any beneficial effects in childhood TBM, 
different baseline characteristics of the patients enrolled might 
have distorted results (10).
There is evidence that suggests an immune-mediated pathoe-
tiology of vascular events in TB patients. Vasculitis in TBM is 
morphologically similar to other immune-mediated vasculitis 
(27) and the anti-inflammatory effect of glucocorticoids has 
successfully been used in treatment of TBM (28) as well as 
TB-IRIS (TB-associated Immune Reconstitution Inflammatory 
Syndrome) (29). Likewise, a recent open-label CT has evaluated 
aspirin in combination with corticosteroids in TBM and found 
a reduction of strokes and mortality (30). Indeed, hyperco-
agulability cannot be uncoupled from inflammatory processes. 
Increased cytokine levels are associated with progression of 
atherosclerosis and development of ischemia in patients with 
stable angina (31), injured epithelia secrete more cytokines 
and cause local inflammation which fuels atherosclerosis (31). 
Atherosclerosis and hypercoagulability are cytokine-mediated 
and thus an inflammatory process, this could explain the benefit 
TAbLe 3 | Non-steroidal anti-inflammatory drugs (NSAIDs) acting as anti-tubercular non-antibiotics (including in vitro studies).
Drug Study implications
Ibuprofen Elvers, antibacterial activity of the anti-inflammatory compound ibuprofen. 
1995. in vitro (34)
Inhibition of Protein translation initiation (inhibition of 
bacterial initiation factor 2) (35, 36)
Ibuprofen and Carprofen Guzman, antitubercular specific activity of ibuprofen and the other 
2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. 
2013. in vitro (36)
Inhibition of DNA replication and repair (acting on 
‘bacterial sliding clamp’ = DNA-polymerase III β) (37)
Aspirin Schaller, salicylate reduces susceptibility of Mycobacterium tuberculosis to 
multiple anti-tuberculosis (TB) drugs. 2002. in vitro (33)
Down-regulating bacterial transcription and translation 
especially genes for energy production (38)
Diclofenac (DCL) Dutta, in vitro and in vivo antimycobacterial activity of antiinflammatory drug, 
DCL sodium. 2004. in vivo and in vitro (18)
Against Gram-positive and Gram-negative bacteria 
possibly by inhibition of bacterial DNA synthesis (39, 40)
Dutta, Activity of DCL used alone and in combination with streptomycin 
against Mycobacterium tuberculosis in mice. 2007. in vivo and in vitro (19)
Sriram, synthesis, in vitro and in vivo antimycobacterial activities of DCL acid 
hydrazones and amides. 2006. in vitro (41)
Celecoxib (Cox-II Selective) Kalle, inhibition of bacterial multidrug resistance by celecoxib, a 
cyclooxygenase-2 inhibitor. 2011. in vitro (42)
Salunke, design and synthesis of novel anti-TB agents from the celecoxib 
pharmacophore. 2015. in vitro (44)
Inhibition of bacterial drug-resistance by inhibiting 
efflux mechanism (regulation of bacterial MDR-1 efflux 
pumps) (43)
Oxyphenbutazole Gold, non-steroidal anti-inflammatory drug sensitizes Mycobacterium 
tuberculosis to endogenous and exogenous antimicrobials. 2012. in vitro (45)
Multifactorial: inhibition of bacterial enzymatic reactions 
by affecting flavins and thiols (32)
NSAIDs bound to 
metal-complexes
Chiniforoshan, anti-inflammatory drugs interacting with Zn (II) metal ion based 
on thiocyanate and azide ligands: synthesis, spectroscopic studies, DFT 
calculations and antibacterial assays. 2014. in vitro (46)
Kovala-Demertzi, Organotin meclofenamic complexes: synthesis, crystal 
structures, and antiproliferative activity of the first complexes of meclofenamic 
acid—novel anti-TB agents. 2009. in vitro (47)
Total 11
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of corticosteroids in TBM and TB-IRIS. The effect of NSAIDs in 
states of inflammatory hypercoagulability of TB should further 
be investigated.
With rising drug-resistances against commonly employed 
anti-TB drugs, new add-on drugs need to be employed, enhanc-
ing anti-mycobacterial efficacy to avoid the need to increase doses 
to potentially toxic levels (31). In vivo data by Dutta et al. suggests 
an enhancing effect of DCL on the TB-antibiotic S as well as an 
own anti-mycobacterial effect of DCL (18). In vitro data equally 
demonstrated some inhibitory effect of many NSAIDs on myco-
bacteria by targeting various biological functions in the bacilli 
(32) (see Table 3). Aspirin reduces the expression of genes for 
energy metabolism in bacteria (33).
Non-steroidal anti-inflammatory drugs as add-on could 
leverage the efficacy of commonly used antibiotic anti-TB drugs, 
but if displaying intrinsic bactericidal activity, development of 
drug-resistance against NSAIDs themselves would have to be 
considered (19). However, most anti-tubercular non-antibiotics 
so far have displayed in  vitro MICs from 10–25  µg/ml, which 
are concentrations beyond clinical achievability (48). However, 
intracellular concentration of NSAIDs by macrophages may 
enhance killing: by phagocytosis, they might concentrate drugs in 
question more than 10× in the phagocytosed target Mtb (48). The 
bactericidal dose might be achievable in situ. Therefore, possible 
benefits of various NSAIDs as anti-tubercular non-antibiotics 
implied by in vitro data (see Table 3) require in vivo and conse-
quently clinical confirmation.
Non-steroidal anti-inflammatory drugs as potential HDT 
would be considered as adjunctive in TB-treatment and would 
be intended to be administered in addition to common anti-TB 
treatment regimens. Thus, interaction mechanisms with com-
monly used anti-TB drugs and alterations of pharmacodynamics 
need to be evaluated. So far, no published study has evaluated 
interaction of NSAIDs with the current full four-drug regimen 
used for human drug-susceptible TB.
Salicylate was found to have in vitro adverse effects in combi-
nation with the first line TB-drugs H, R, E, and Streptomycin (S) 
(33). In contrast, in in vivo combination with the first line TB-drug 
Z it showed synergistic effect (15). Z is converted to pyrazinoic 
acid and needs an acidic pH for full efficacy, which increases as 
the metabolism of the mycobacterium decreases. This is why 
it acts best against dormant, persistent Mtb (49). Microarray 
data suggest that salicylates cause a de-energized status in Mtb 
by down-regulating translation and transcription of genes for 
energy production (38). This is supported by the fact that aspirin 
enhanced the effect of Z in vivo, but not in vitro (15). This does 
however not explain the synergistic effect of ibuprofen in com-
bination with Z. Byrne et al. suggest that an anti-inflammatory 
mechanism via reduction of PGs was less likely, as this would 
antagonize the acidic pH built in inflammation needed for action 
of Z (15). However, since the efficacy of Z is not pH-dependent 
despite a slightly acidic pH optimum, the excessive inflammation 
might reduce its efficacy, which is the case for the other anti-TB 
drugs as well.
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Currently, four CTs are ongoing to evaluate the effect of 
NSAIDs during TB treatment. The anti-inflammatory proper-
ties of NSAIDs seem of potential benefit in TB-IRIS (29): an 
ongoing trial is evaluating the benefit of meloxicam in TB-IRIS 
(NCT02060006). Based on the findings by Vilaplana et al. (13), 
a pilot study is currently conducted in Georgia, to assess the 
potential safety and efficacy of ibuprofen as an add-on in the 
treatment of pre-XDR and XDR-TB patients (NCT02781909). 
Moreover, there is a pilot study on the way, which aims to evaluate 
the benefit of low-dose (75 mg/day) and high-dose aspirin: 1 g/
day (much higher than in Schoeman et al. (100 mg/day) (10) as 
an adjunctive to anti-TB treatment of HIV-negative adults with 
TBM (NCT02237365). Shroff et al. found that the non-responder 
state of mice to M. vaccae by i.p. route of immunization was cor-
rected by pre-treatment with indomethacin (16); and this strategy 
should be evaluated for other therapeutic vaccines as well. In this 
sense, there is an ongoing CT (NCT02503839) evaluating the 
concurrent administration of a COX-2 inhibitor (etoricoxib) and 
a therapeutic vaccine in addition to conventional TB-treatment 
in MDR-TB. In vitro and in vivo data showed that DCL and many 
other NSAIDs have direct bactericidal properties (see Table 3) 
(18). A CT is evaluating the bactericidal ex vivo activity of 
celecoxib (a COX-selective NSAID) against Mtb in whole blood 
from healthy volunteers (NCT02602509).
In conclusion, and despite open questions that should be 
addressed in further research and the well-known side effects, 
NSAIDs potentially have beneficial effect in treatment of TB (8, 
13). Even if most of the evidence is limited to preclinical studies 
and consequently clinical studies are warranted for confirmation 
of safety and efficacy, NSAIDs could be a secure, simple, and 
(depending on the NSAID drug) a cheap adjunction for future 
TB (including MDR/XDR-TB)-treatment regimens.
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